These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30450529)

  • 1. Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia.
    Beljić Živković TM; Đinđić BJ; Šuluburić Toljić DŽ; Vulović KTM; Udovičić DL; Zdravković DZ
    Diabetes Ther; 2019 Feb; 10(1):71-80. PubMed ID: 30450529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study.
    Velojic-Golubovic M; Ciric V; Dimitrijevic M; Kovic T; Mitic M; Olujic B; Pevac N; Radenkovic S; Radojkovic D; Vukadinovic S; Popovic DS
    Diabetes Ther; 2021 Jul; 12(7):2049-2058. PubMed ID: 34160790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study).
    Brož J; Janíčková Žďárská D; Urbanová J; Piťhová P; Doničová V; Pálová S; Pelechová B; Smržová A; Kvapil M
    Diabetes Ther; 2021 Jul; 12(7):1799-1808. PubMed ID: 34028699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.
    Gomez-Peralta F; Al-Ozairi E; Jude EB; Li X; Rosenstock J
    Diabetes Obes Metab; 2021 Jul; 23(7):1445-1452. PubMed ID: 33651460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.
    Giugliano D; Tracz M; Shah S; Calle-Pascual A; Mistodie C; Duarte R; Sari R; Woo V; Jiletcovici AO; Deinhard J; Wille SA; Kiljanski J
    Diabetes Care; 2014 Feb; 37(2):372-80. PubMed ID: 24170763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designer insulins regimens in clinical practice--pilot multicenter Indian study.
    Joshi SR; Kalra S; Badgandi M; Rao YS; Chawla M
    J Assoc Physicians India; 2005 Sep; 53():775-9. PubMed ID: 16334621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study.
    Aschner P; Sethi B; Gomez-Peralta F; Landgraf W; Loizeau V; Dain MP; Pilorget V; Comlekci A
    J Diabetes Complications; 2015 Aug; 29(6):838-45. PubMed ID: 25981123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Validation Survey to Assess Usage of Premix Insulins in Management of Diabetes with Respect to the Recommendations Enlisted in Indian Guidelines.
    Kalra S; Sahay R; Tiwaskar M; Priya G; Das S; Bantwal G
    J Assoc Physicians India; 2020 Jun; 68(6):20-25. PubMed ID: 32610874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
    Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Meneghini LF; Mauricio D; Orsi E; Lalic NM; Cali AMG; Westerbacka J; Stella P; Candelas Dea C; Pilorget V; Perfetti R; Khunti K;
    Diabetes Obes Metab; 2019 Jun; 21(6):1429-1436. PubMed ID: 30768845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study.
    Bjekić-Macut J; Živković TB; Kocić R
    Diabetes Ther; 2018 Apr; 9(2):651-662. PubMed ID: 29460260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.